Ablynx passes first clinical hurdle with RANKL-targeting nanobody
This article was originally published in Scrip
Executive Summary
Ablynx's RANK-L targeting bone-disease drug ALX-0141 is safe, show preliminary data from a Phase I trial. Although ALX-0141 still has many developmental hurdles to jump, it is the only challenger to Amgen's first-in-class, approved, RANKL-targeting antibody Prolia (denosumab) to make it into the clinic.